Kardium Inc., an emerging leader in advanced solutions for atrial fibrillation, is proud to announce the publication of the PULSAR clinical trial results in the Journal of the American College of Cardiology (JACC). This landmark study evaluated the Globe^® Pulsed Field System by Kardium for the treatment of paroxysmal atrial fibrillation (PAF).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121865382/en/

The Globe mapping and ablation catheter from Kardium.

The multicenter pivotal trial demonstrated that the Globe System achieved durable pulmonary vein isolation (PVI) in 95% of veins with only one pulsed field application, while maintaining a 0% device-related primary safety event rate. At 12 months, 78% of patients remained free from atrial arrhythmias, further underscoring the effectiveness of the system in treating drug-refractory PAF.

“The Globe Pulsed Field System has the potential to transform how we treat atrial fibrillation by delivering durable pulmonary vein isolation with remarkable efficiency and safety,” said Dr. Vivek Reddy, Principal Investigator of the trial. “These results show that this technology can make a real difference for patients, offering them better outcomes and a safer path to long term relief from arrhythmias.”

"The PULSAR pivotal trial highlights how the Globe Pulsed Field System can deliver consistent, durable outcomes with an exceptional safety profile. These results represent an important step forward in advancing treatment options for patients with paroxysmal atrial fibrillation, and we are proud to share this work with the global cardiology community,” said Dr. Atul Verma, Co-Principal Investigator of the trial.

“The publication of the PULSAR pivotal trial results in JACC is a tremendous validation of the safety, efficacy and efficiency of the Globe System. At Kardium, we are committed to delivering the most advanced system for the treatment of atrial fibrillation,” said Kevin Chaplin, Chief Executive Officer of Kardium.

The study enrolled 183 patients across leading centers in North America and Europe, with procedures showing efficiency in mapping, ablation, and overall treatment times.

About the PULSAR Trial

The PULSAR pivotal IDE trial (NCT05462145) evaluated the safety and effectiveness of the Globe Pulsed Field System in patients with symptomatic paroxysmal atrial fibrillation. The study was sponsored by Kardium Inc. and conducted at 12 international centers with leading electrophysiologists.

About Kardium

We are a rapidly growing, privately held medical solutions company with a mission to deliver the best treatment for atrial fibrillation through the Globe Pulsed Field System. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has be recognized as a top company to work for in BC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121865382/en/